MedWatch

Olympus upgrades after Covid-19 recovery

Sales have increased in the US, Europe, and its homecountry of Japan, reports medtech company Olympus, as it upgrades its operating profit expectations for the next financial year.

Japanese Olympus, a competitor to Danish Ambu within the endoscope market, has upgraded its guidance for the skewed fiscal year 2021/2022. The Japenese company now thinks full-year operating profits of JPY 144bn (USD 1.27bn) are likely, up from JPY 140bn (USD 1.23bn).

According to analysts' estimates collected by Bloomberg News, this was an anticipated move after the Olympus's operating profits ended the 2020/2021 fiscal year at JPY 143.29bn (USD 1.26bn).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs